Recently, there has been real-world evidence on the effects of GLP-1 receptor agonists (GLP-1RAs) and long-acting insulins (LAIs) on kidney health in type 2 diabetes patients who need intensive blood sugar control and have a high risk for CKD progression. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.